Long-Term miR-669a Therapy Alleviates Chronic Dilated Cardiomyopathy in Dystrophic Mice

Long-Term miR-669a Therapy Alleviates Chronic Dilated Cardiomyopathy in Dystrophic Mice

Dilated cardiomyopathy (DCM) is a leading cause of chronic morbidity and mortality in muscular dystrophy (MD) patients. Current pharmacological treatments are not yet able to counteract chronic myocardial wastage, thus novel therapies are being intensely explored. MicroRNAs have been implicated as f...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the American Heart Association. Cardiovascular and Cerebrovascular Disease 2013, Vol.2 (4), p.1-10
Hauptverfasser: Quattrocelli, Mattia, Crippa, Stefania, Montecchiani, Celeste, Camps, Jordi, Cornaglia, Antonia Icaro, Boldrin, Luisa, Morgan, Jennifer, Calligaro, Alberto, Casasco, Andrea, Orlacchio, Aldo, Gijsbers, Rik, D'hooge, Jan, Toelen, Jaan, Janssens, Stefan, Sampaolesi, Maurilio
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Dilated cardiomyopathy (DCM) is a leading cause of chronic morbidity and mortality in muscular dystrophy (MD) patients. Current pharmacological treatments are not yet able to counteract chronic myocardial wastage, thus novel therapies are being intensely explored. MicroRNAs have been implicated as fine regulators of cardiomyopathic progression. Previously, miR-669a downregulation has been linked to the severe DCM progression displayed by Sgcb-null dystrophic mice. However, the impact of long-term overexpression of miR-669a on muscle structure and functionality of the dystrophic heart is yet unknown.
ISSN:2047-9980
2047-9980